Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Small-molecule inhibition of SMYD5-mediated rpl40 methylation as a therapeutic strategy in gastric adenocarcinoma
FY 2025-26
Summary
Gastric adenocarcinoma (GAC) is one of the most lethal cancers worldwide, largely due to late diagnosis when treatment options are limited. Recent studies have shown that increased expression of SET and MYND domain-containing protein 5 (SMYD5) in GAC patients suggests that it may serve as a potential biomarker and therapeutic target. SMYD5 catalyzes the trimethylation of ribosomal protein L40 (rpl40) at lysine 22 (rpl40K22me3), a modification that enhances global protein synthesis and promotes tumour progression. However, small-molecule inhibitors targeting SMYD5 have not yet been investigated, representing a critical gap in gastric cancer therapy.
This project aims to determine whether the inhibition of SMYD5 can suppress protein synthesis and reduce tumour cell proliferation in GAC. Aim 1 will identify small-molecule SMYD5 inhibitors from the NIH/NCATS compound library using high-throughput methyltransferase screening with recombinant SMYD5 and rpl40. Hits will be validated using a 384-well plate SAH-detection assay, and molecular docking will predict inhibitor–SMYD5 interactions. Aim 2 will evaluate target engagement and functional effects of inhibitors in GAC cell models using cellular thermal shift assay (CETSA) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively. Ribosome profiling will characterize changes in translational activity.
This study aims to investigate the cellular activity and therapeutic potential of SMYD5 inhibition in gastric adenocarcinoma, thereby laying the groundwork for novel targeted treatments.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572874
Name
Chow Man-Tung
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Small-molecule inhibition of SMYD5-mediated rpl40 methylation as a therapeutic strategy in gastric adenocarcinoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cancer Therapeutic; Cancer Therapeutics; Epigenetic Regulation; Gastric Adenocarcinoma; High-Throughout Screening; Lysine Methyltransferase; Sah-Detection Assay; Smyd5; Translation Elongation; Tumour Cell Proliferation
Abstract
Gastric adenocarcinoma (GAC) is one of the most lethal cancers worldwide, largely due to late diagnosis when treatment options are limited. Recent studies have shown that increased expression of SET and MYND domain-containing protein 5 (SMYD5) in GAC patients suggests that it may serve as a potential biomarker and therapeutic target. SMYD5 catalyzes the trimethylation of ribosomal protein L40 (rpl40) at lysine 22 (rpl40K22me3), a modification that enhances global protein synthesis and promotes tumour progression. However, small-molecule inhibitors targeting SMYD5 have not yet been investigated, representing a critical gap in gastric cancer therapy.
This project aims to determine whether the inhibition of SMYD5 can suppress protein synthesis and reduce tumour cell proliferation in GAC. Aim 1 will identify small-molecule SMYD5 inhibitors from the NIH/NCATS compound library using high-throughput methyltransferase screening with recombinant SMYD5 and rpl40. Hits will be validated using a 384-well plate SAH-detection assay, and molecular docking will predict inhibitor–SMYD5 interactions. Aim 2 will evaluate target engagement and functional effects of inhibitors in GAC cell models using cellular thermal shift assay (CETSA) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively. Ribosome profiling will characterize changes in translational activity.
This study aims to investigate the cellular activity and therapeutic potential of SMYD5 inhibition in gastric adenocarcinoma, thereby laying the groundwork for novel targeted treatments.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Chow, Man-Tung
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~